Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-07-20, 11:47:43 | version 1.38.0
23 Inplant Tribune United Kingdom Edition | 6/2016 IMPLANT BUSINESS Education is key. We believe that it is very important that clini- cians start the thought process for the clinical workflow early. We have some programmes in place already and will promote these programmes to help and support universities in the education of young dentists in implantology. For example, we support aca- demic institutions and dental stu- dents through the provision of NobelClinician Software licences for implant planning and patient communication. Only recently, voters in the UK de- cided that the country should leave the European Union.How could the Brexit affect the dental industry and are there any immediate con- cerns for Nobel Biocare? This is a question that is really difficult to answer, as the short- and long-term consequences of the Brexit remain unclear. I be- lieve that even experts cannot predict the impact of the Brexit on the industry. From a personal point of view, I believe it is never a good thing to have many sepa- rate markets. However, whether the Brexit will affect us as Nobel Biocare directly, I do not yet know. How has the acquisition by the dental platform of the Danaher Corporation, which occurred at the end of 2014, affected Nobel Biocare’s business? We have seen only positive effects. The transition into the dental platform has given us new opportunitiestodevelopresources for innovation, marketing and sales that we would not have had without this partnership. Collabo- ration with other brands within the platform has opened up ex- pertise that is allowing us to lead innovation in dentistry. We are learning from our colleagues and have gained tools that are helping us to refine our processes and accelerate results. The new home of Nobel Biocare is a very good one. The next big occasion in the dental event schedule is the International Dental Show in March next year. Are there even more innovations to come from Nobel Biocare? I cannot disclose anything yet. However, I can tell you already that there will be significant innova- tions presented. The potential that we are going to bring to the market will be of the same magnitude as that experienced at the sympo- sium over the past few days. Nobel Biocare will accelerate its delivery of significant and meaningful innovations, each de- veloped with the well-being of the patient in mind. Thank you very much. By DTI BARCELONA, Spain: Founded in 1995, MIS Implants Technologies started out as a small implant company in the discount seg- ment, but has developed into a successful global business over the past 20 years. At a press con- ferenceheldduringtheMISGlobal Conference in Barcelona in May, the management team gave a de- tailed outlook on the company’s future strategic developments, product innovations and poten- tial growth markets. In order to pursue considera- ble growth and address challenges in the implant market, MIS made a number of organisational changes to the company structure several years ago. One of these was in- tegrating research and develop- ment functions into the market- ing and sales department, a move thattransformedthedepartment’s way of working. Since 2013, Doron Peretz, Senior Vice President of Marketing and Development, has been guiding the R & D division at MIS. “Thekeytocontinuousgrowth is innovation. However, it is not easy to drive innovations from in-house. Therefore, our market- ing team, who is most exposed to the current opportunities of the market, has contributed a lot to exploring and bringing new ideas to research and development, and we are progressing rapidly in ex- panding our portfolio with this approach,” he said. MIS management identified three markets offering opportu- nities for considerable growth, namely Germany, the US and China, where MIS only recently opened a new subsidiary. “Despite the vast number of dentists, the number of implants sold in China today is similar to the number in Israel. However, we be- lieve that the situation will change when we train more dentists on how to use dental implants. Therefore, we are investing in education in par- ticular,” Peretz told Dental Tribune. He further explained: “Today, the dental implant market is divided into the premium, the value and the discount segment. We predict that about five years from now this will no longer be the case. The main reason is that dentists will no longer accept low- value discount implants. MIS is currently leading the value seg- ment and will continue to do so.” Peretz also disclosed that the company is planning to bring a number of new products to market over the next three years, including the next generation of the V3 Implant System, which will be launched at the upcoming International Dental Show in March 2017. With some of these in- novations, MIS is aiming to offer its customers products in the pre- mium range. “In order to really grow, we have to participate in the premium segment, which cur- rently accounts for about 70 per cent of the global implant mark- et. We have to develop solutions and services that can compete against other products and bring added value in this segment,” he said. MIS CEO Idan Kleifeld added: “Today, it is crucial to offer com- plete solutions and in line with our philosophy ‘Make it Simple’, our primary principle is to sim- plify every stage of the implan- tology process. The combination of mechanical design of the V3, biological properties of the new B+ implant surface, and digital technology with the MGUIDE, al- lows us to provide clinicians with highly effective solutions that produce safe and predictable re- sults.” “We want to become the most innovative company in implant dentistry and we are now close to fulfilling this aim with our latest developments,” Kleifeld concluded. To continue leading the value market Dental implant manufacturer MIS announces future strategies MIS Implants Technology presenting its new B+ implant surface treatment at its Global Conference in Barcelona. Doron Peretz, Senior Vice President of Marketing and Development. © Claudia Duschek/DTI “ Page 21 “...dentists will no longer accept low-value discount implants.”